NcXHF

GERIATRIC ONCOLOGY AND CLINICAL TRIALS
4. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical
trials for cancer drug registration: a 7-year experience by the US Food
and Drug Administration. J Clin Oncol. 2004;22:4626-4631.
5. Wildiers H, Mauer M, Pallis A, et al. End points and trial design in geriatric
oncology research: a joint European organisation for research
and treatment of cancer-Alliance for Clinical Trials in Oncology-
International Society of Geriatric Oncology position article. J Clin Oncol.
2013;31:3711-3718.
6. Lichtman SM. Commentary. How do we get more patients into clinical
trials? Oncology (Huntingt). 2007;21:363-364.
7. Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial
participation by older women with breast cancer [published correction
appears in J Clin Oncol. 2004;2004;4811]. J Clin Oncol. 2003;21:2268-
2275.
8. Kornblith AB, Kemeny M, Peterson BL, et al. Survey of oncologists’ perceptions
of barriers to accrual of older patients with breast carcinoma to
clinical trials. Cancer. 2002;95:989-996.
9. Lichtman SM. Call for changes in clinical trial reporting of older patients
with cancer. J Clin Oncol. 2012;30:893-894.
10. Levit LA, Balogh E, Nass SJ, et al. (eds). Delivering high-quality cancer
care: charting a new course for a system in crisis. Washington, D.C: National
Academies Press; 2013.
11. Bouchardy C, Rapiti E, Blagojevic S, et al. Older female cancer patients:
importance, causes, and consequences of undertreatment. J Clin Oncol.
2007;25:1858-1869.
12. Begg CB, Cohen JL, Ellerton J. Are the elderly predisposed to toxicity
from cancer chemotherapy? An investigation using data from the Eastern
Cooperative Oncology Group. Cancer Clin Trials. 1980;3:369-374.
13. Kennedy BJ. Needed: clinical trials for older patients. J Clin Oncol. 1991;
9:718-720.
14. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in
cancer treatment trials. Cancer. 1994;74:2208-2214.
15. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence
of oncology specialists, and hospital cancer programs affect accrual
to cancer treatment trials. J Clin Oncol. 2002;20:2109-2117.
16. Scher KS, Hurria A. Under-representation of older adults in cancer registration
trials: known problem, little progress. J Clin Oncol. 2012;30:
2036-2038.
17. Lichtman SM. Clinical trial design in older adults with cancer—the need
for new paradigms. J Geriatr Oncol. 2012;3:368-375.
18. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional
status are independent in older cancer patients. J Clin Oncol. 1998;
16:1582-1587.
19. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity
in older adults with cancer: a prospective multicenter study. J Clin Oncol.
2011;29:3457-3465.
20. Audisio RA, Pope D, Ramesh HS, et al. Shall we operate? Preoperative
assessment in elderly cancer patients (PACE) can help. A SIOG surgical
task force prospective study. Crit Rev Oncol Hematol. 2008;65:156-163.
21. Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age
in survival of patients treated with chemotherapy for aggressive non-
Hodgkin’s lymphoma. J Clin Oncol. 1988;6:1838-1844.
22. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen
with or without irradiation in women 70 years of age or older with early
breast cancer. N Engl J Med. 2004;351:971-977.
23. Satariano WA, Ragland DA. The effect of comorbidity on 3-year survival
of women with primary breast cancer. Ann Intern Med. 1994;120:
104-110.
24. Johansson JE, Adami HO, Andersson SO, et al. High 10-year survival
rate in patients with early, untreated prostatic cancer. JAMA. 1992;267:
2191-2196.
25. Newschaffer CJ, Otani K, McDonald MK, et al. Causes of death in elderly
prostate cancer patients and in a comparison nonprostate cancer
cohort. J Natl Cancer Inst. 2000;92:613-621.
26. Fries JF. Aging, natural death, and the compression of morbidity. N Engl
J Med. 1980;303:130-135.
27. Fries JF. Measuring and monitoring success in compressing morbidity.
Ann Intern Med. 2003;139:455-459.
28. Bouvier AM, Jooste V, Bonnetain F, et al. Adjuvant treatments do not
alter the quality of life in elderly patients with colorectal cancer: a
population-based study. Cancer. 2008;113:879-886.
29. Hilpert F, du Bois A, Greimel E, et al. Feasibility, toxicity and quality of
life of fırst-line chemotherapy with platinum/paclitaxel in elderly patients
aged 70 years with advanced ovarian cancer-a study by the
AGO OVAR Germany. Ann Oncol. 2007;18:282-287.
30. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and
functional status assessment signifıcantly predict survival of elderly patients
with advanced non-small-cell lung cancer receiving chemotherapy:
a prognostic analysis of the multicenter Italian lung cancer in the
elderly study. J Clin Oncol. 2005;23:6865-6872.
31. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival
and clinical benefıt with gemcitabine as fırst-line therapy for patients
with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;
15:2403-2413.
32. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl
J Med. 2004;351:1502-1512.
33. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone
plus prednisone or prednisone alone for symptomatic hormoneresistant
prostate cancer: a Canadian randomized trial with palliative
end points. J Clin Oncol. 1996;14:1756-1764.
34. High K, Bradley S, Loeb M, et al. A new paradigm for clinical investigation
of infectious syndromes in older adults: assessing functional status
as a risk factor and outcome measure. J Am Geriatr Soc. 2005;53:528-
535.
35. Cheung WY, Neville BA, Cameron DB, et al. Comparisons of patient
and physician expectations for cancer survivorship care. J Clin Oncol.
2009;27:2489-2495.
36. Earle CC. Cancer survivorship research and guidelines: maybe the cart
should be beside the horse. J Clin Oncol. 2007;25:3800-3801.
37. Rowland JH, Hewitt M, Ganz PA. Cancer survivorship: a new challenge
in delivering quality cancer care. J Clin Oncol. 2006;24:5101-5104.
38. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship
statistics, 2014. CA Cancer J Clin. 2014;64:252-271.
39. McCabe M. A challenge of survivorship-healing the mind and spirit.
Oncology (Williston Park). 2008;22:9.
40. McCabe MS. Looking beyond survival survivorship care is critical to the
future of oncology. Oncology (Williston Park). 2007;21:398.
41. McCabe MS, Jacobs L. Survivorship care: models and programs. Semin
Oncol Nurs. 2008;24:202-207.
42. Borkowski JM, Duerr M, Donehower RC, et al. Relation between age
and clearance rate of nine investigational anticancer drugs from
phase I pharmacokinetic data. Cancer Chemother Pharmacol. 1994;
33:493-496.
43. Weber JS, Levit LA, Adamson PC, et al. American Society of Clinical
Oncology policy statement update: the critical role of phase I trials in
cancer research and treatment. J Clin Oncol. 2015;33:278-284.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e131